These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 25829248)

  • 1. Comparisons of hospitalization rates among younger atrial fibrillation patients receiving different antiarrhythmic drugs.
    Allen LaPointe NM; Dai D; Thomas L; Piccini JP; Peterson ED; Al-Khatib SM
    Circ Cardiovasc Qual Outcomes; 2015 May; 8(3):292-300. PubMed ID: 25829248
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiarrhythmic drug use in patients <65 years with atrial fibrillation and without structural heart disease.
    Allen LaPointe NM; Dai D; Thomas L; Piccini JP; Peterson ED; Al-Khatib SM
    Am J Cardiol; 2015 Feb; 115(3):316-22. PubMed ID: 25491240
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of antiarrhythmic medications on the risk of cardiovascular outcomes in patients with atrial fibrillation and coronary artery disease.
    Wang SR; Huang KC; Lin TT; Chuang SL; Yang YY; Wu CK; Lin LY
    Int J Cardiol; 2024 Aug; 409():132198. PubMed ID: 38782070
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative effectiveness of antiarrhythmic drugs for rhythm control of atrial fibrillation.
    Qin D; Leef G; Alam MB; Rattan R; Munir MB; Patel D; Khattak F; Adelstein E; Jain SK; Saba S
    J Cardiol; 2016 May; 67(5):471-6. PubMed ID: 26233885
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of dronedarone in patients previously treated with other antiarrhythmic agents.
    Guerra F; Hohnloser SH; Kowey PR; Crijns HJ; Aliot EM; Radzik D; Roy D; Connolly S; Capucci A
    Clin Cardiol; 2014 Dec; 37(12):717-24. PubMed ID: 25470298
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-World Comparison of Classes IC and III Antiarrhythmic Drugs as an Initial Rhythm Control Strategy in Newly Diagnosed Atrial Fibrillation: From the TREAT-AF Study.
    Kipp R; Askari M; Fan J; Field ME; Turakhia MP
    JACC Clin Electrophysiol; 2019 Feb; 5(2):231-241. PubMed ID: 30784696
    [TBL] [Abstract][Full Text] [Related]  

  • 7. One-year treatment persistence and potential adverse events among patients with atrial fibrillation treated with amiodarone or sotalol: a retrospective claims database analysis.
    Kim MH; Smith PJ; Jhaveri M; Lin J; Klingman D
    Clin Ther; 2011 Nov; 33(11):1668-1681.e1. PubMed ID: 22108302
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design and rationale of a randomized study to compare amiodarone and Class IC anti-arrhythmic drugs in terms of atrial fibrillation treatment efficacy in patients paced for sinus node disease: the PITAGORA trial.
    Gulizia M; Mangiameli S; Chiarandà G; Spadola V; Di Giovanni N; Colletti A; Bulla V; Circo A; Pensabene O; Vasquez L; Vaccaro I; Grammatico A;
    Europace; 2006 Apr; 8(4):302-5. PubMed ID: 16627459
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiovascular outcomes in the AFFIRM Trial (Atrial Fibrillation Follow-Up Investigation of Rhythm Management). An assessment of individual antiarrhythmic drug therapies compared with rate control with propensity score-matched analyses.
    Saksena S; Slee A; Waldo AL; Freemantle N; Reynolds M; Rosenberg Y; Rathod S; Grant S; Thomas E; Wyse DG
    J Am Coll Cardiol; 2011 Nov; 58(19):1975-85. PubMed ID: 22032709
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An individual patient-based meta-analysis of the effects of dronedarone in patients with atrial fibrillation.
    Hohnloser SH; Connolly SJ; John Camm A; Halperin JL; Radzik D
    Europace; 2014 Aug; 16(8):1117-24. PubMed ID: 24728270
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized comparison of amiodarone and class IC antiarrhythmic drugs to treat atrial fibrillation in patients paced for sinus node disease: the Prevention Investigation and Treatment: A Group for Observation and Research on Atrial arrhythmias (PITAGORA) trial.
    Gulizia M; Mangiameli S; Orazi S; Chiarandà G; Piccione G; Di Giovanni N; Colletti A; Pensabene O; Lisi F; Vasquez L; Grammatico A; Boriani G;
    Am Heart J; 2008 Jan; 155(1):100-7, 107.e1. PubMed ID: 18082498
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcomes Associated with Dronedarone Use in Patients with Atrial Fibrillation.
    Goehring EL; Bohn RL; Pezzullo J; Tave AK; Jones JK; Bozzi S; Tamayo RCSG; Sicignano N; Naccarelli GV
    Am J Cardiol; 2020 Nov; 135():77-83. PubMed ID: 32861738
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ventricular arrhythmia and death among atrial fibrillation patients using anti-arrhythmic drugs.
    Friberg L
    Am Heart J; 2018 Nov; 205():118-127. PubMed ID: 30236980
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Limited duration of antiarrhythmic drug use for newly diagnosed atrial fibrillation in a nationwide population under age 65.
    D'Angelo RN; Rahman M; Khanna R; Yeh RW; Goldstein L; Yadalam S; Kalsekar I; Tung P; Zimetbaum PJ
    J Cardiovasc Electrophysiol; 2021 Jun; 32(6):1529-1537. PubMed ID: 33760297
    [TBL] [Abstract][Full Text] [Related]  

  • 15. International cohort study on the effectiveness of dronedarone and other antiarrhythmic drugs for atrial fibrillation in real-world practice (EFFECT-AF).
    Khachatryan A; Merino JL; de Abajo FJ; Botto GL; Kirchhof P; Breithardt G; Stambler B; Abenhaim L; Grimaldi-Bensouda L
    Europace; 2022 Jul; 24(6):899-909. PubMed ID: 34792111
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiarrhythmic effect of ranolazine in combination with class III drugs in an experimental whole-heart model of atrial fibrillation.
    Frommeyer G; Milberg P; Uphaus T; Kaiser D; Kaese S; Breithardt G; Eckardt L
    Cardiovasc Ther; 2013 Dec; 31(6):e63-71. PubMed ID: 23647657
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use and outcomes of antiarrhythmic therapy in patients with atrial fibrillation receiving oral anticoagulation: results from the ROCKET AF trial.
    Steinberg BA; Hellkamp AS; Lokhnygina Y; Halperin JL; Breithardt G; Passman R; Hankey GJ; Patel MR; Becker RC; Singer DE; Hacke W; Berkowitz SD; Nessel CC; Mahaffey KW; Fox KA; Califf RM; Piccini JP;
    Heart Rhythm; 2014 Jun; 11(6):925-32. PubMed ID: 24833235
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rhythm- and rate-controlling effects of dronedarone in patients with atrial fibrillation (from the ATHENA trial).
    Page RL; Connolly SJ; Crijns HJ; van Eickels M; Gaudin C; Torp-Pedersen C; Hohnloser SH;
    Am J Cardiol; 2011 Apr; 107(7):1019-22. PubMed ID: 21296333
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Guideline-Concordant Antiarrhythmic Drug Use in the Get With The Guidelines-Atrial Fibrillation Registry.
    Field ME; Holmes DN; Page RL; Fonarow GC; Matsouaka RA; Turakhia MP; Lewis WR; Piccini JP;
    Circ Arrhythm Electrophysiol; 2021 Feb; 14(2):e008961. PubMed ID: 33419385
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Significance of atrial fibrillation during acute myocardial infarction, and its current management: insights from the GUSTO-3 trial.
    Wong CK; White HD; Wilcox RG; Criger DA; Califf RM; Topol EJ; Ohman EM
    Card Electrophysiol Rev; 2003 Sep; 7(3):201-7. PubMed ID: 14739713
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.